Clover Health Investments 주식 (NASDAQ: CLOV)

에 대한 최신 뉴스 Clover Health Investments (NASDAQ:CLOV) 주식

Clover Health Investments

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. Operating in two segments, Insurance and Non-Insurance, Clover Health offers PPO and HMO plans to Medicare Advantage members in multiple states through its Insurance segment. In the Non-Insurance segment, the company participates in the ACO REACH Model. The majority of revenue is generated from the insurance segment, reflecting the significance of its healthcare insurance offerings.

Equities

News

Markets

CLOV

JOBY

NVDA

PLTR

TSLA

미국 주요 지수들이 수요일에 긍정적인 흐름으로 마감되었다. 다우존스 산업평균지수는 0.09% 상승하여 42,196.52로 마감했고, S&amp;P 500지수는 0.01% 상승하여 5,709.54에 도달했다. 나스닥 지수도 0.08% 상승하여 17,925.12로 마감했다.

수요일 주목받은 주식 5종목: 엔비디아, 팔란티어, 클로버 헬스, 조비 에비에이션 및 테슬라

Health Care

Movers

클로버 헬스 인베스트먼트(NASDAQ:CLOV)의 주식은 거래량이 증가하고 소셜 미디어 플랫폼 전반에 걸쳐 관심을 끌면서 수요일 29% 이상 급등했다.

클로버 헬스의 주식이 수요일 29% 이상 급등: 무슨 일이?

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments Corp

CLOVER CORP LTD by Clover Corporation Ltd.

CLOVER LEAF CAP CORP RT

CLOVIS ONCOLOGY ORD

Clover Finance - United States Dollar

CLOVER LEAF CAPITAL A by Clover Leaf Capital Corp.

Clover Leaf Capital Corp

Clover Leaf Capital Corp Units (1 Ord Share Class A & 1 Right)

CLOVERLEAF KENNEL CLB A by Cloverleaf Kennel Club

Cloverleaf Kennel Club

Clovis Oncology Inc

Lake Street analyst Jaeson Schmidt maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $60 to $41.

Price Target

Analyst Ratings

NSSC

Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $41

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) .

Guidance

GIFI

Gulf Island Fabrication expect FY2024 adjusted consolidated EBITDA of $11M-$13M.

Lake Street analyst Eric Martinuzzi maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Hold and raises the price target from $20 to $25.

QNST

Lake Street Maintains Hold on QuinStreet, Raises Price Target to $25

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) .

SNDX

Syndax Pharmaceuticals FY2024 R&D expenses forecast: $245M-$250M.

Loop Capital analyst Rob Sanderson maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Buy and raises the price target from $14 to $16.

SNAP

Loop Capital Maintains Buy on Snap, Raises Price Target to $16

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) .

GPOR

Gulfport Energy Full Year 2024: Drilling and completion capex guidance cut to $325M-$335M.

Loop Capital analyst Garik Shmois maintains Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) with a Buy and lowers the price target from $105 to $100.

Loop Capital Maintains Buy on Knife River Holding, Lowers Price Target to $100

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $330 to $280.

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $280

It's Election day! Voters are visiting polling locations and social media mavens are sharing opinions and local reports in megathreads, polls and comments on Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Here are some notable threads to follow for election <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">coverage on Reddit.&nbsp;</a>
Polls Open: Subreddit r/politics has over 8.5 million subscribers and features a <a href="https://www.reddit.com/r/politics/comments/1gkefi6/rpolitics_2024_us_elections_live_thread_part_59/">live thread</a> with 59 parts titled, "2024 US Elections Live Thread, Part 59" which contains more than 3,200 comments, voter turnout reports from different locations and live commentary on election developments.&nbsp;
Subreddit r/moderatepolitics has 295,000 members and a <a href="https://www.reddit.com/r/moderatepolitics/">poll titled</a> "Who are you voting for in the 2024 US Presidential Election." At the time of publication, 2,100 Redditors selected Harris, 1,300 selected Trump, 301 selected Other and 842 responded with Not Voting.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41612293/reddit-stock-soars-after-strong-q3-results-q4-guidance-above-estimates-dauqs-grow-17-and-more">Reddit Stock Soars After Strong Q3 Results, Q4 Guidance Above Estimates: DAUq&#8217;s Grow 17% And More</a>
Reddit also features local subreddits like r/Pennsylvania, which has <a href="https://www.reddit.com/r/Pennsylvania/comments/1gjutyd/the_election_day_mega_thread/">a thread</a> titled, "The Election Day Mega Thread" where users can find coverage of the crucial swing state and voting guides and polling locations. The thread also provides local polling updates and news with first-hand accounts from voters across the state.&nbsp;
Where To Find Results: FiveThirtyEight, the data journalism outlet, will feature county-by-county data breakdowns as the polling results come in at its r/fivethirtyeight <a href="https://www.reddit.com/r/fivethirtyeight/">subreddit</a>. It also features discussions about polling accuracy and several live election megathreads.&nbsp;&nbsp;
The r/Journalism <a href="https://www.reddit.com/r/Journalism/">subreddit</a> will provide authoritative sources for results, including updates from the Associated Press and major networks, as well as discussions about result reporting methodology.&nbsp;
Reddit&#8217;s election coverage offers a blend of real-time updates and community engagement across various specialized subreddits, though most users recommend keeping multiple sources open for the most complete picture.&nbsp;
RDDT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Reddit shares ended Tuesday&#8217;s session 12.42% higher at $122.57.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">JPMorgan To Pay Investors $151 Million After SEC Flags &#8216;Various Law Violations&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

Politics

Tech

General

RDDT

Redditors Track Election Night: Must-Watch Threads For Trump Vs. Harris Showdown, Other Races

WIIM

WillScot Holdings shares are trading higher following a report suggesting activist investor TOMS has built a stake in the company and is pushing for a review.

JP Morgan analyst Kevin Yin upgrades Yum China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) from Neutral to Overweight and raises the price target from $35.5 to $60.

Upgrades

YUMC

JP Morgan Upgrades Yum China Holdings to Overweight, Raises Price Target to $60

With the first polling places about to close in what is <a href="https://www.benzinga.com/general/politics/24/11/41748843/trump-holds-edge-in-betting-markets-on-election-day-while-experts-call-tight-race-for-harris">expected to be a neck-and-neck election night</a>, reports from Georgia and Michigan say those two swing states are seeing record-high turnout.
What Happened: Turnout in Philadelphia is also reported to be extremely high, with Reuters reporting turnout as much as 50% higher in some precincts than in 2020. A big win in Philadelphia would go a long way toward delivering Pennsylvania &#8211; the largest and tightest swing state &#8211; to Kamala Harris.
At 4:39 p.m. EDT, Donald Trump wrote on Truth Social: &#8220;A lot of talk about massive CHEATING in Philadelphia. Law Enforcement coming!!!&#8221; 
A Philadelphia police spokesman <a href="https://fortune.com/2024/11/05/donald-trump-claims-cheating-police-philadelphia-pennsylvania/">told Fortune</a> they are &#8220;not aware of anything at this time.&#8221; 
Charlie Kirk of pro-Trump group Turning Point Action wrote earlier on X: &#8220;Turnout is mixed and not where we want it to be. We need more people to vote.&#8221;
Also Read: <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">2024 Election Stakes: Potential Sweeps, Split Outcomes In Congressional, Presidential Races</a>
Politico is <a href="https://www.politico.com/live-updates/2024/11/05/2024-elections-live-coverage-updates-analysis/turnout-high-in-georgia-00187458">reporting</a> that turnout in Georgia is on track to surpass 2020, and The Hill <a href="https://thehill.com/homenews/campaign/4973132-michigan-on-pace-to-break-voter-turnout-records-official-says/">says</a> that Michigan may break turnout records.
Why It Matters: High turnout in Philadelphia would be good news for Harris, but even a loss in Pennsylvania would not be fatal to Trump if he performs well in other swing states.
Georgia, Michigan and Pennsylvania were all key to Joe Biden&#8216;s victory in 2020.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">Trump Vs. Harris: 2024 Election Deadlocked, Final Emerson Poll Shows One Candidate With Small Edge Among Independents</a></li>
</ul>
Image: Shutterstock.

High Turnout Reported In Key States, Trump Baselessly Alleges 'Massive CHEATING' In Philadelphia

A new study <a href="https://tandfonline.com/doi/full/10.1080/21507740.2024.2303154">published</a> in AJOB Neuroscience reveals that most Americans are supportive of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost <a href="https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/">reported</a>, this approval, spanning across political lines, underscores public openness to the controlled use of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin for mental health treatment</a> and general well-being, despite remaining concerns for policy caution.
Psilocybin, a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule 1</a> drug in the U.S., has long been classified as having a high potential for abuse with no accepted medical use. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">recent clinical studies</a> suggest it may help alleviate symptoms of conditions such as treatment-resistant depression when administered under professional supervision. Unlike many medications, psilocybin is considered non-addictive, and studies have found it may also <a href="https://www.benzinga.com/markets/cannabis/24/09/41004196/psilocybin-found-to-be-as-effective-as-lexapro-in-treating-depression-researchers-say">enhance overall well-being</a> in healthy individuals.
This research aimed to explore public perceptions of psilocybin amid <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">recent legislative progress</a>, such as Oregon&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">allowing its therapeutic use</a>. Researchers surveyed 805 Americans, aged 18 to 92, providing background on psilocybin's effects, origin and legal status before asking about support for nationwide legalization.
<h3 class="wp-block-heading">Mental Health Treatment Vs. Well-Being Enhancement</h3>
Participants were presented with two scenarios involving supervised psilocybin use: one for mental health treatment and the other for personal well-being. A strong 89% of participants supported psilocybin use for mental health treatment, while 85% approved its use for well-being enhancement. Though medical use garnered slightly more support, both scenarios saw broad endorsement.
The results show bipartisan support for supervised psychedelic therapy, with younger and more liberal adults showing stronger approval. Older adults and conservatives were more cautious, while those valuing empathy and care were more supportive of psilocybin use in therapy
<h3 class="wp-block-heading">Navigating Caution Amid The Psychedelic Renaissance</h3>
The study also sheds light on the importance of tempering enthusiasm with scientific rigor. According to the researchers, the growing interest in psychedelics comes with the risk of overhyping benefits. Given the early stage of the field, both over- and understatements of trial results are not uncommon. As they noted, while psilocybin shows significant medical potential and a strong safety profile, current evidence doesn&#8217;t support rash conclusions beyond its use in the right context.
While the findings suggest broad public support for supervised psychedelic use, the study focused only on licensed environments, excluding unsupervised or recreational use. Future research could explore attitudes toward these higher-risk aspects.
<h3 class="wp-block-heading">Building Trust And Policy For The Future</h3>
The study authors stressed the need for trust-building and caution in shaping future policies. "If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust—then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being," they concluded.
With public support reaching bipartisan levels, the potential for psilocybin to become part of standard mental health care is closer to reality than ever, signaling a transformative shift in mental health treatment in the U.S.
Cover image made with AI

Cannabis

Psychedelics

Americans Favor Psilocybin For Mental Health Treatment, Study Finds

DA Davidson analyst Brian Holland maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $183 to $189.

FRPT

DA Davidson Maintains Buy on Freshpet, Raises Price Target to $189

Hut 8 Says Its Self-Mining Produced 100 BTC In October, Up From 85 BTC In September; Vega Site Buildout Advancing On Track For Q2 2025 Energization

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and lowers the price target from $94 to $90.

DA Davidson Maintains Neutral on Federal Signal, Lowers Price Target to $90

DA Davidson maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $55 to $48.

DA Davidson Maintains Buy on NAPCO Security Techs, Lowers Price Target to $48

Emerson and its affiliates currently own 57.4% of the Company's outstanding common shares, based on their most recent Schedule 13D filing dated November 5, 2024.
The Board of Directors of AspenTech will follow an appropriate governance process and carefully review the proposal. No action is required by AspenTech shareholders at this time. &nbsp;

AZPN

Aspen Technology Confirms Receipt Of $240/Share Unsolicited Acquisition Proposal From Emerson; Asks Shareholders Not To Take Any Action Pending Review

DA Davidson analyst Brent Thielman maintains Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) with a Neutral and raises the price target from $41 to $47.

DA Davidson Maintains Neutral on Summit Materials, Raises Price Target to $47

PAAS

Pan American Silver Reaffirms Its 2024 Operating Outlook For Annual Production, Cash Costs And AISC, And Capital Expenditures

Clover Health started at neutral by UBS, improving operations cited

The latest announcement is out from Clover Health Investments ( ($CLOV) ). Clover Health Investments, Corp. has announced a CMS rating upgrade for ...

Clover Health Earns 4-Star CMS Rating, Anticipates Growth

Clover gains, Humana dips as Medicare finalizes 2025 Star Ratings

Clover gains, Humana dips as Medicare finalizes 2025 Star Ratings (update)

Most major U.S. managed care insurers set for sequential earnings declines in Q3

Analyst Richard Close from Canaccord Genuity maintained a Buy rating on Clover Health Investments (CLOV – Research Report) and keeping the price ta...

Clover Health: A Strong Buy on 4-Star Rating and Competitive Edge

UnitedHealth dips as cost concerns weigh on insurance unit

Attention Bulls; Rising Risk After Election Day, More Than Before

Attention Bulls: Big Earnings Week, Great Trading Setup, With 5 Dislocation Points

Clover Health Q3 2024 Earnings Preview

AAPL

ALHC

AMZN

APLD

EXPE

GOOG

GOOGL

MSFT

OSCR

SOFI

SPXL

SPXS

TQQQ

UBER

VKTX

Press Releases

Clover Health to Participate in Upcoming 2024 Wells Fargo Healthcare Conference

Management

Thomas L. Tran, Former Chief Financial Officer of Molina Healthcare, Joins Clover Health's Board of Directors

Contracts

The Iowa Clinic Signs Multi-Year Agreement with Counterpart Health to Deploy Proven AI Technology to Hundreds of Providers Across the Midwest

Fit to Work: Intelligent Bio Solutions' (NASDAQ: INBS) Vision for a Healthier, Safer Workplace WISA, BFLY, CLOV, PRSO

Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations

Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer

Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025

2025 Clover Health Medicare Advantage Benefits Demonstrate Commitment to New Jersey Seniors

Clover Health to Report Third Quarter 2024 Financial Results on November 6

Clover Health to Participate in Upcoming Investor Conferences

BFLY

INBS

PRSO

WISA

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Centene

Elevance Health

HealthEquity

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Citigroup

Canaccord Genuity

Credit Suisse

SVB Leerink

미국 주요 지수들이 수요일에 긍정적인 흐름으로 마감되었다. 다우존스 산업평균지수는 0.09% 상승하여 42,196.52로 마감했고, S&amp;P 500지수는 0.01% 상승하여 5,709.54에 도달했다. 나스닥 지수도 0.08% 상승하여 17,925.12로 마감했다.
소매 거래자와 투자자들의 관심을 끌었던 주요 주식들은 다음과 같다:
엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아는 1.58% 상승하여 $118.85로 거래를 마쳤으며, 하루 중 최고가와 최저가는 각각 $119.38와 $115.14였다. 엔비디아의 52주 최고가는 $140.76, 최저가는 $39.23이다. 또한, 엔비디아와 액센츄어는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41151741/nvidias-ai-leadership-to-drive-1-trillion-market-growth-with-accenture-partnership-">기업 내 AI 도입을 가속화하기 위한 파트너십</a>을 발표했다. 웨드 부시(Wedbush Securities)의 애널리스트 댄 아이브스에 따르면, 이 협력은 엔비디아 주식에 긍정적인 영향을 미칠 것으로 보인다.
팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
팔란티어의 주식은 2.83% 상승하여 $37.49로 마감했다. 주식은 하루 중 최고가가 $37.68, 최저가가 $36.15에 도달했다. 52주 최고가는 $38.19, 최저가는 $14.48이다. 팔란티어의 주가가 상승한 이유는 공동 창립자이자 의장인 피터 틸(Peter Thiel)이 <a href="https://www.benzinga.com/news/24/10/41145602/palantir-stock-is-moving-higher-wednesday-whats-going-on">매각 계획에 따라 최대 주식을 매각 완료했다는 보도</a>가 나온 후 주가가 상승한 것이다.
클로버 헬스 인베스트먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>)
클로버 헬스는 29.14% 상승하여 $3.59로 마감했다. 주식은 하루 중 최고가가 $3.65, 최저가가 $2.74에 도달했다. 52주 최고가는 $3.82, 최저가는 $0.61이다. 이 회사 주식이 상승한 이유는 거래량 증가와 소셜 미디어에서의 관심이 높아졌기 때문이다. 지난달, 클로버 헬스의 자회사인 카운터파트 헬스(Counterpart Health)가 <a href="https://www.benzinga.com/news/24/10/41150683/clover-health-stock-surges-over-29-on-high-volume-recap">아이오와 클리닉과의 다년간 계약을 발표</a>한 바 있다.
조비 에비에이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)
조비 에비에이션의 주식은 27.92% 상승하여 $6.14로 마감되었다. 주식은 하루 중 최고가가 $6.32, 최저가가 $5.19에 도달했다. 52주 최고가는 $7.69, 최저가는 $4.5이다. 이 회사 주식이 상승한 이유는 토요타 자동차(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>)가 <a href="https://www.benzinga.com/markets/equities/24/10/41146425/toyota-doubles-down-on-joby-aviation-500m-investment-powers-us-electric-air-taxi-certification-p">전기 항공 택시 인증 및 상업 생산 지원을 위한 추가 투자 5억 달러</a>를 발표한 후 주식이 상승했다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주식은 3.49% 하락하여 $249.02로 마감되었다. 주식은 하루 중 최고가가 $251.16, 최저가가 $241.50에 도달했다. 52주 최고가는 $271, 최저가는 $138.80다. 두 분기 연속 매출이 감소한 후, 테슬라는 3분기 인도가 예상치를 초과했다고 보고했지만, 주가가 하락한 이유는 예상보다 낮은 숫자와 주요 모델 판매에 대한 우려 때문이다. 애널리스트들은 <a href="https://www.benzinga.com/news/24/10/41141444/tesla-stock-plunges-3-despite-q3-deliveries-exceeding-consensus-and-growing-year-over-year">3분기 실적이 긍정적일 것이라고 예상</a>하지만, 로보택시 공개 및 향후 매출 및 주가 성과에 대한 잠재적 영향과 같은 향후 이벤트에 대한 견해가 혼재되어 있다.
이미지 출처: Shutterstock
벤징가와 함께 <a href="Premarket Movers &amp; News">당일 거래를 위한 주요 프리마켓 동향 및 뉴스</a>를 준비하세요.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41087674/openais-searchgpt-set-to-disrupt-googles-search-empire-as-former-engineer-sounds-alarm-on-deteriorat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">오픈AI의 서치GPT가 구글의 검색 제국을 파괴할 것으로 예상되며, 전 엔지니어가 경쟁 심화로 인한 사용자 경험 악화에 대해 경고</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 생성되었고, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

클로버 헬스 인베스트먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>)의 주식은 거래량이 증가하고 소셜 미디어 플랫폼 전반에 걸쳐 관심을 끌면서 수요일 29% 이상 급등했다.
다음은 <a href="https://www.benzinga.com/news/24/10/41144935/rpm-international-posts-upbeat-earnings-joins-joby-aviation-ciena-and-other-big-stocks-moving-higher">알아야 할 사항들이다.</a>
Counterpart Health와 아이오와 클리닉의 협약: 지난달 클로버 헬스(Clover Health)의 자회사인 카운터파트 헬스(Counterpart Health)가 아이오와 클리닉(Iowa Clinic)과 다년간의 협약을 체결했다. 아이오와 클리닉의 메디케어 어드밴티지(Medicare Advantage) 및 메디케어 공유 저축 프로그램 환자들을 담당하는 클리니션들은 조기 진단 및 만성 질환 관리에 도움을 주는 AI 기반 솔루션인 카운터파트 어시스턴트(Counterpart Assistant)를 사용할 것이다.
이 기술은 미드웨스트 전역의 아이오와 클리닉의 임상 통합 네트워크 파트너들에게도 제공된다. 카운터파트 헬스는 회원당 월별 수수료와 특정 관리 목표 달성에 따른 인센티브 지급을 받을 수 있다.
아이오와 클리닉의 CEO인 벤 발리어(Ben Vallier)는 카운터파트가 임상 데이터를 활용하여 결과를 개선하고, 클리니션들의 필요에 맞춘 직관적인 디자인을 갖춘 점을 높이 평가했다.
신임 COO 임명: 클로버 헬스는 또한 메디케어 어드밴티지 운영을 담당할 신임 최고 운영책임자(COO)로 조셉 브랜드(Joseph Brand)를 임명했다. 브랜드는 제퍼슨 헬스 플랜(Jefferson Health Plans)의 COO로 최근 20년 가까이 의료 분야에서 리더십 경험을 가지고 있으며, 운영 효율성과 기술 혁신을 통해 뉴저지의 의료 서비스 개선에 집중할 것이다.
기타 사항: 클로버 헬스의 공매도 비율이 마지막 보고서 이후 9.75% 감소하여, 2,936만 주가 공매도 되었으며, 이는 유통 주식의 7.31%를 나타낸다. 소셜 미디어 플랫폼, 특히 레딧(Reddit)의 r/WallStreetBets에서 클로버 헬스에 대한 활발한 논의가 이루어지고 있다.
CLOV 주가 움직임: 클로버 헬스의 주식은 수요일 29.14% 상승하여 $3.59에 마감되었다. 이후 시간외 거래에서 0.84% 추가 상승했다.
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-577343" style="width: 548px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-1024x538.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV-768x403.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02155228/CLOV.png 1087w" alt="" width="1024" height="538" /></a></figure>
사진 제공: CloverHealth Inc.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Clover Health Investments

뉴스

에 대한 최신 뉴스 Clover Health Investments (NASDAQ:CLOV) 주식

목요일, 10월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌